Patents by Inventor Harshani R. Lawrence

Harshani R. Lawrence has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BRD4-kinase inhibitors as cancer therapeutics
    Patent number: 11643396
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: May 9, 2023
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • BRD4-JAK2 INHIBITORS
    Publication number: 20220119370
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
    Type: Application
    Filed: September 9, 2019
    Publication date: April 21, 2022
    Inventors: Ernst SCHÖNBRUNN, Nicholas J. LAWRENCE, Harshani R. LAWRENCE, Gary REUTHER
  • BRD4-JAK2 INHIBITORS
    Publication number: 20210355088
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I, II, and II.
    Type: Application
    Filed: September 9, 2019
    Publication date: November 18, 2021
    Inventors: Ernst SCHÖNBRUNN, Nicholas J. LAWRENCE, Harshani R. LAWRENCE, Gary REUTHER
  • BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
    Publication number: 20200407328
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 31, 2020
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • BRD4-kinase inhibitors as cancer therapeutics
    Patent number: 10738016
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: August 11, 2020
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • Proteasome chymotrypsin-like inhibition using PI-1833 analogs
    Patent number: 10662180
    Abstract: Focused library synthesis and medicinal chemistry on an oxadiazole-isopropylamide core proteasome inhibitor provided the lead compound that strongly inhibits CT-L activity. Structure activity relationship studies indicate the amide moiety and two phenyl rings are sensitive toward synthetic modifications. Only para-substitution in the A-ring was important to maintain potent CT-L inhibitory activity. Hydrophobic residues in the A-ring's para-position and meta-pyridyl group at the B-ring significantly improved inhibition. The meta-pyridyl moiety improved cell permeability. The length of the aliphatic chain at the para position of the A-ring is critical with propyl yielding the most potent inhibitor, whereas shorter (i.e. ethyl, methyl or hydrogen) or longer (i.e. butyl, propyl and hexyl) chains demonstrating progressively less potency. Introduction of a stereogenic center next to the ether moiety (i.e.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: May 26, 2020
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Harshani R. Lawrence, Said M. Sebti, Sevil Ozcan
  • Potent dual BRD4-kinase inhibitors as cancer therapeutics
    Patent number: 10526291
    Abstract: Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: January 7, 2020
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence, Gary W. Reuther
  • Inhibitors of ACK1/TNK2 tyrosine kinase
    Patent number: 10336734
    Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new ACK1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I are disclosed.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: July 2, 2019
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
  • POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
    Publication number: 20190055203
    Abstract: Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
    Type: Application
    Filed: October 22, 2018
    Publication date: February 21, 2019
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • Potent dual BRD4-kinase inhibitors as cancer therapeutics
    Patent number: 10106507
    Abstract: Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: October 23, 2018
    Assignee: H. Lee Moffitt Cancer Center and Research Insitute, Inc.
    Inventors: Ernst Shönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
    Publication number: 20180290984
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
    Type: Application
    Filed: October 13, 2016
    Publication date: October 11, 2018
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • INHIBITORS OF ACK1/TNK2 TYROSINE KINASE
    Publication number: 20180215738
    Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new ACK1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I are disclosed.
    Type: Application
    Filed: August 2, 2016
    Publication date: August 2, 2018
    Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
  • PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS
    Publication number: 20180215742
    Abstract: Focused library synthesis and medicinal chemistry on an oxadiazole-isopropylamide core proteasome inhibitor provided the lead compound that strongly inhibits CT-L activity. Structure activity relationship studies indicate the amide moiety and two phenyl rings are sensitive toward synthetic modifications. Only para-substitution in the A-ring was important to maintain potent CT-L inhibitory activity. Hydrophobic residues in the A-ring's para-position and meta-pyridyl group at the B-ring significantly improved inhibition. The meta-pyridyl moiety improved cell permeability. The length of the aliphatic chain at the para position of the A-ring is critical with propyl yielding the most potent inhibitor, whereas shorter (i.e. ethyl, methyl or hydrogen) or longer (i.e. butyl, propyl and hexyl) chains demonstrating progressively less potency. Introduction of a stereogenic center next to the ether moiety (i.e.
    Type: Application
    Filed: January 29, 2018
    Publication date: August 2, 2018
    Inventors: Harshani R. Lawrence, Said M. Sebti, Sevil Ozcan
  • Inhibitors of ACK1/TNK2 tyrosine kinase
    Patent number: 10017478
    Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: July 10, 2018
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
  • INHIBITORS OF ACK1/TNK2 TYROSINE KINASE
    Publication number: 20180155297
    Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.
    Type: Application
    Filed: November 9, 2017
    Publication date: June 7, 2018
    Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
  • Proteasome chymotrypsin-like inhibition using PI-1833 analogs
    Patent number: 9878999
    Abstract: Focused library synthesis and medicinal chemistry on an oxadiazole-isopropylamide core proteasome inhibitor provided the lead compound that strongly inhibits CT-L activity. Structure activity relationship studies indicate the amide moiety and two phenyl rings are sensitive toward synthetic modifications. Only para-substitution in the A-ring was important to maintain potent CT-L inhibitory activity. Hydrophobic residues in the A-ring's para-position and meta-pyridyl group at the B-ring significantly improved inhibition. The meta-pyridyl moiety improved cell permeability. The length of the aliphatic chain at the para position of the A-ring is critical with propyl yielding the most potent inhibitor, whereas shorter (i.e. ethyl, methyl or hydrogen) or longer (i.e. butyl, propyl and hexyl) chains demonstrating progressively less potency. Introduction of a stereogenic center next to the ether moiety (i.e.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: January 30, 2018
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Harshani R. Lawrence, Said M. Sebti, Sevil Ozcan
  • Inhibitors of ACK1/TNK2 tyrosine kinase
    Patent number: 9850216
    Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: December 26, 2017
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
  • POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
    Publication number: 20170226065
    Abstract: Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
    Type: Application
    Filed: August 3, 2015
    Publication date: August 10, 2017
    Inventors: Ernst SHÖNBRUNN, Nicholas J. LAWRENCE, Harshani R. LAWRENCE
  • Aurora kinase inhibitors and methods of making and using thereof
    Patent number: 9597329
    Abstract: Described herein are inhibitors of Aurora kinase and their use in the treatment of cancer. Methods of screening for selective inhibitors of Aurora kinases are also disclosed.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: March 21, 2017
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc
    Inventors: Said M. Sebti, Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence, Matthew P. Martin
  • AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF
    Publication number: 20170000787
    Abstract: Described herein are inhibitors of Aurora kinase and their use in the treatment of cancer. Methods of screening for selective inhibitors of Aurora kinases are also disclosed.
    Type: Application
    Filed: February 1, 2016
    Publication date: January 5, 2017
    Applicant: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Said M. Sebti, Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence, Matthew P. Martin